In compliance with Regulation 30 of the SEBI Listing Regulations, Abbott India has informed about the following: 1) Resignation of Senior Management Personnel Murari Ranganathan, Commercial Director - Women’s Health, Metabolics and International Business, has tendered his resignation from employment of the Company with effect from close of business hours of February 25, 2025, to pursue opportunities outside the Company. Pursuant to his resignation, he will also cease to be the Senior Management Personnel of the Company effective the said date. The details required to be disclosed as per SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023 is enclosed. Pursuant to Regulation 30 read with Clause 7C of Para A of Part A of Schedule Ill of the SEBI Listing Regulations, the letter of resignation of Murari Ranganathan along with reasons shall be shared separately within seven days from the date the resignation comes into effect. 2) Appointment of Senior Management Personnel Prithwish Kumar Banerji has been appointed as Commercial Director - Women’s Health, Metabolics and International Business with effect from January 3, 2025. In accordance with the SEBI Listing Regulations, Prithwish will be considered as Senior Management Personnel of the Company. The additional details required under the SEBI Listing Regulations read with SEBI Circular No. CIR/CFD/CMD/412015 dated September 9, 2015 is enclosed as Annexure A.
The above information is a part of company’s filings submitted to BSE.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1826.10 |
Dr. Reddys Lab | 1371.60 |
Cipla | 1488.15 |
Lupin | 2251.80 |
Zydus Lifesciences | 1009.40 |
View more.. |